Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Breed Reply is the Internet of Things-focused venture investing and acceleration arm associated with Reply. It funds and operationally supports early-stage companies, primarily in IoT-related markets such as health, fitness and wellness, smart buildings and cities, security, industrial IoT, big data, platforms, and drones. The organization appears to function as a corporate venture investor and accelerator rather than a drug-development biotech or healthcare operating company. Public descriptions indicate it has been active for roughly a decade and is now focused primarily on managing and supporting its existing portfolio. For a biotech analyst, Breed Reply is best understood as a strategic technology investor with some exposure to digital health and wellness, not as a therapeutics developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Breed Reply.